Literature DB >> 9810558

Two cases of chromosome 4q35-linked early onset facioscapulohumeral muscular dystrophy with mental retardation and epilepsy.

K Miura1, T Kumagai, A Matsumoto, E Iriyama, K Watanabe, K Goto, K Arahata.   

Abstract

Two cases of early onset facioscapulohumeral muscular dystrophy (FSHD) with mental retardation and epilepsy are reported. They were sporadic, unrelated, severely affected females. In both cases, Southern blot analysis of the EcoRI-digested genomic DNA, using probes p13E-11 and pFR-1, detected the shortest 10 kb EcoRI fragments reported to date. Patient 1 showed infantile spasms at the age of 4 months and localization-related epilepsy at the age of 2.5 years. Muscular atrophy in the face, shoulder girdle and upper arms was observed from the age of 4 years. In Patient 2, lack of facial expression was noticed since the age of 1 year, and at 4 years she was noted to have a loss of bilateral upward gaze. She developed localization-related epilepsy at the age of 9 years. From the age of 10 years, weakness of the lower limbs progressed and she became wheelchair-bound at the age of 14 years and 8 months. She had moderate sensorineural hearing loss, a loss of bilateral upward gaze and tongue atrophy. Their IQs were 33 and 45, respectively. The two patients suggest that mental retardation and epilepsy may be part of the clinical spectrum of FSHD, especially in very early onset patients with large deletions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9810558     DOI: 10.1055/s-2007-973568

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  11 in total

1.  Mechanism and timing of mitotic rearrangements in the subtelomeric D4Z4 repeat involved in facioscapulohumeral muscular dystrophy.

Authors:  Richard J L F Lemmers; Petra G M Van Overveld; Lodewijk A Sandkuijl; Harry Vrieling; George W Padberg; Rune R Frants; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2004-05-20       Impact factor: 11.025

2.  Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy.

Authors:  Richard J F L Lemmers; Mariëlle Wohlgemuth; Rune R Frants; George W Padberg; Eva Morava; Silvere M van der Maarel
Journal:  Am J Hum Genet       Date:  2004-10-04       Impact factor: 11.025

3.  Genetic counseling and testing for FSHD (facioscapulohumeral muscular dystrophy) in the Israeli population.

Authors:  Miri Yanoov-Sharav; Esther Leshinsky-Silver; Sarit Cohen; Chana Vinkler; Marina Michelson; Tally Lerman-Sagie; Mira Ginzberg; Menahem Sadeh; Dorit Lev
Journal:  J Genet Couns       Date:  2011-11-23       Impact factor: 2.537

Review 4.  The D4Z4 repeat-mediated pathogenesis of facioscapulohumeral muscular dystrophy.

Authors:  Silvère M van der Maarel; Rune R Frants
Journal:  Am J Hum Genet       Date:  2005-01-24       Impact factor: 11.025

Review 5.  The cell biology of disease: FSHD: copy number variations on the theme of muscular dystrophy.

Authors:  Daphne Selvaggia Cabianca; Davide Gabellini
Journal:  J Cell Biol       Date:  2010-12-13       Impact factor: 10.539

6.  Validation of Optical Genome Mapping for the Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy.

Authors:  Aaron A Stence; Jon G Thomason; Jonathan A Pruessner; Ramakrishna R Sompallae; Anthony N Snow; Deqin Ma; Steven A Moore; Aaron D Bossler
Journal:  J Mol Diagn       Date:  2021-08-09       Impact factor: 5.568

7.  Terminal 4q deletion syndrome.

Authors:  C M Kuldeep; A K Khare; Anubhav Garg; Asit Mittal; Lalit Gupta
Journal:  Indian J Dermatol       Date:  2012-05       Impact factor: 1.494

8.  Rbfox1 downregulation and altered calpain 3 splicing by FRG1 in a mouse model of Facioscapulohumeral muscular dystrophy (FSHD).

Authors:  Mariaelena Pistoni; Lily Shiue; Melissa S Cline; Sergia Bortolanza; Maria Victoria Neguembor; Alexandros Xynos; Manuel Ares; Davide Gabellini
Journal:  PLoS Genet       Date:  2013-01-03       Impact factor: 5.917

9.  Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles: experience of the FSHD Italian National Registry.

Authors:  Ana Nikolic; Giulia Ricci; Francesco Sera; Elisabetta Bucci; Monica Govi; Fabiano Mele; Marta Rossi; Lucia Ruggiero; Liliana Vercelli; Sabrina Ravaglia; Giacomo Brisca; Chiara Fiorillo; Luisa Villa; Lorenzo Maggi; Michelangelo Cao; Maria Chiara D'Amico; Gabriele Siciliano; Giovanni Antonini; Lucio Santoro; Tiziana Mongini; Maurizio Moggio; Lucia Morandi; Elena Pegoraro; Corrado Angelini; Antonio Di Muzio; Carmelo Rodolico; Giuliano Tomelleri; Maria Grazia D'Angelo; Claudio Bruno; Angela Berardinelli; Rossella Tupler
Journal:  BMJ Open       Date:  2016-01-05       Impact factor: 2.692

10.  Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.

Authors:  Samantha LoRusso; Nicholas E Johnson; Michael P McDermott; Katy Eichinger; Russell J Butterfield; Elena Carraro; Kiley Higgs; Leann Lewis; Karlien Mul; Sabrina Sacconi; Valeria A Sansone; Perry Shieh; Baziel van Engelen; Kathryn Wagner; Leo Wang; Jeffrey M Statland; Rabi Tawil
Journal:  BMC Neurol       Date:  2019-09-10       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.